To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with congestive heart failure and preserved systolic function after 12 years of evaluation.

The investigators will verify patients with cardiac heart failure (CHF) and preserved systolic function and each patient must have all clinical evaluation through basal measurements of blood pressure, heart rate, biochemical tests, and color Doppler echocardiographic parameters for at least 12 years.

The investigators will evaluate the effects of an aldosterone antagonist as canrenone compared to a group without canrenone and the investogators will verify how many patients reported cardiovascular mortality or will survive.

Inclusion Criteria:

• patients with CHF
• preserved systolic function (FE ≥ 45%)

Exclusion Criteria:

• severe hypertension identified by blood pressure ≥180/110 mmHg
• patients with impaired systolic function (FE < 45%)
• history of active hepatitis or cirrhosis
• impaired renal function
• hyperpotassemia
• diabetes

Patients with CHF and preserved systolic function with or without an aldosterone antagonist as canrenone.